In vivo studies also suggest that overexpression of ExomiR-770 directly targets STMN1, a stathmin family phosphoprotein involved in intracellular signaling, thereby increasing doxorubicin sensitivity via inducing apoptosis and decreasing the tumour volume and metastasis (Li Y. et al., 2018) and (Table 2). This evidence concerns the gene STMN1 and neoplasm.